Vaccination reduces viral load and accelerates viral clearance in SARS-CoV-2 Delta variant-infected patients

References

• Gebru AA, Birhanu T, Wendimu E, et al. Global burden of COVID-19: situational analyis and review. Hum Antibodies. 2021;29(2):139–148.
   PubMedGoogle Scholar
• Supasa P, Zhou D, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell. 2021;184(8):2201–2211.e7.
   PubMed Web of Science ®Google Scholar
• Thiagarajan K. Why is India having a covid-19 surge? BMJ. 2021;373:n1124.
   PubMedGoogle Scholar
• The Lancet India’s COVID-19 emergency. Lancet. 2021;397(10286):1683.
   PubMed Web of Science ®Google Scholar
• Raman R, Patel KJ, Ranjan K. COVID-19: unmasking emerging SARS-CoV-2 variants, vaccines and therapeutic strategies. Biomolecules. 2021;11(7):993.
   PubMed Web of Science ®Google Scholar
• Wall EC, Wu M, Harvey R, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021;397(10292):2331–2333.
   PubMed Web of Science ®Google Scholar
• Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593(7857):130–135.
   PubMed Web of Science ®Google Scholar
• Sheikh A, McMenamin J, Taylor B, et al. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461–2462.
   PubMed Web of Science ®Google Scholar
• Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385(7):585–594.
   PubMed Web of Science ®Google Scholar
• Mouliou DS, Pantazopoulos I, Gourgoulianis KI. COVID-19 smart diagnosis in the emergency department: all-in in practice. Expert Rev Respir Med. 2022;16(3):263–272.
   PubMed Web of Science ®Google Scholar
• Mouliou DS, Gourgoulianis KI. COVID-19 ‘asymptomatic’ patients: an old wives’ tale. Expert Rev Respir Med. 2022;16(4):399–407.
   PubMed Web of Science ®Google Scholar
• Mouliou DS, Gourgoulianis KI. False-positive and false-negative COVID-19 cases: respiratory prevention and management strategies, vaccination, and further perspectives. Expert Rev Respir Med. 2021;15(8):993–1002.
   PubMed Web of Science ®Google Scholar
• Farooqi T, Malik JA, Mulla AH, et al. An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies. J Infect Public Health. 2021;14(10):1299–1312.
   PubMed Web of Science ®Google Scholar
• Harris RJ, Hall JA, Zaidi A, et al. Effect of vaccination on household transmission of SARS-CoV-2 in England. N Engl J Med. 2021;385(8):759–760.
   PubMed Web of Science ®Google Scholar
• Levine-Tiefenbrun M, Yelin I, Katz R, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021;27(5):790–792.
   PubMed Web of Science ®Google Scholar
• Harder T, Külper-Schiek W, Reda S, et al. Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021. Euro Surveill. 2021;26:2100920.
   PubMedGoogle Scholar
• Hughes EC, Amat JAR, Haney J, et al. Severe acute respiratory syndrome coronavirus 2 serosurveillance in a patient population reveals differences in virus exposure and antibody-mediated immunity according to host demography and healthcare setting. J Infect Dis. 2021;223(6):971–980.
   PubMed Web of Science ®Google Scholar
• Mouliou DS, Kotsiou OS, Gourgoulianis KI. Estimates of COVID-19 risk factors among social strata and predictors for a vulnerability to the infection. IJERPH. 2021;18(16):8701.
   Web of Science ®Google Scholar
• Mouliou DS, Pantazopoulos I, Gourgoulianis KI. Social response to the vaccine against COVID-19: the underrated power of influence. JPM. 2021;12(1):15.
   Google Scholar
• Malik JA, Ahmed S, Mir A, et al. The SARS-CoV-2 mutations versus vaccine effectiveness: new opportunities to new challenges. J Infect Public Health. 2022;15(2):228–240.
   PubMed Web of Science ®Google Scholar
• Zheng C, Chang Z, Liu F, et al. Interpretation of the protocol for prevention and control of COVID-19 in China (Edition 7). China CDC Weekly. 2020;2(47):902–905.
   Google Scholar
• NHC. http://www.nhc.gov.cn/yzygj/s7653p/202008/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a/files/a449a3e2e2c94d9a856d5faea2ff0f94.pdf. (accessed Aug 19, 2020).
   Google Scholar
• Zhang J, Xiao T, Cai Y, et al. Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant. Science. 2021;374(6573):1353–1360.
   Web of Science ®Google Scholar
• Kumar V, Singh J, Hasnain SE, et al. Possible link between higher transmissibility of alpha, kappa and delta variants of SARS-CoV-2 and increased structural stability of its spike protein and hACE2 affinity. IJMS. 2021;22(17):9131.
   Google Scholar
• Campbell F, Archer B, Laurenson-Schafer H, et al. Increased transmissibility and global spread of SARSCoV-2 variants of concern as at June 2021. Euro Surveill. 2021;26:2100509.
   PubMedGoogle Scholar
• Singanayagam A, Hakki S, Dunning J, et al. ATACCC study investigators. Community transmission and viral load kinetics of the SARS-CoV-2 Delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis. 2021;21:e363.
   Google Scholar
• Grant R, Charmet T, Schaeffer L, et al. Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: results from a nationwide case-control study in France. Lancet Reg Health Eur. 2022 Feb;13:100278.
   Google Scholar
• Cai C, Liu Y, Zeng S, et al. The efficacy of COVID-19 vaccines against the B.1.617.2 (Delta) variant. Mol Ther. 2021;29(10):2890–2892.
   PubMed Web of Science ®Google Scholar
• Pouwels KB, Pritchard E, Matthews PC, et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med. 2021;27(12):2127–2135.
   PubMed Web of Science ®Google Scholar
• Mouliou DS, Dardiotis E. Current evidence in SARS-CoV-2 mRNA vaccines and post-vaccination adverse reports: knowns and unknowns. Diagnostics (Basel). 2022;12(7):1555.
   Web of Science ®Google Scholar
• Malik JA, Mulla AH, Farooqi T, et al. Targets and strategies for vaccine development against SARS-CoV-2. Biomed Pharmacother. 2021;137:111254.
   PubMed Web of Science ®Google Scholar
• Pierobon A, Zotto AD, Antico A, et al. Outbreak of SARS-CoV-2 B.1.617.2 (Delta) variant in a nursing home 28 weeks after two doses of mRNA anti-Covid-19 vaccines: evidence of a waning immunity. ClinMicrobiol Infect. 2022;28(4):614.e5–614.e7.
   Google Scholar
• Trachootham D, Thongyen S, Lam-Ubol A, et al. Simultaneously complete but not partial taste and smell losses were associated with SARS-CoV-2 infection. Int J Infect Dis. 2021;106:329–337.
   PubMed Web of Science ®Google Scholar
• Ong SWX, Chiew CJ, Ang LW, et al. Clinical and virological features of SARS-CoV-2 variants of concern: a retrospctive cohort study comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta). Clin Infect Dis. 2022;75(1):e1128–e1136.
   PubMed Web of Science ®Google Scholar
• Luo CH, Morris CP, Sachithanandham J, et al. Infection with the SARS-CoV-2 Delta variant is associated with higher recovery of infectious virus compared to the Alpha variant in both unvaccinated and vaccinated individuals. Clin Infect Dis. 2022;75(1):e715–e725.
   PubMed Web of Science ®Google Scholar
• Basse C, Diakite S, Servois V, Institut Curie COVID Group, et al. Characteristics and outcome of SARS-CoV-2 infection in cancer patients. JNCI Cancer Spectr. 2021;5(1):pkaa090.
   PubMed Web of Science ®Google Scholar
• Karimzadeh S, Bhopal R, Nguyen Tien H. Review of infective dose, routes of transmission and outcome of COVID-19 caused by the SARS-COV-2: comparison with other respiratory viruses. Epidemiol Infect. 2021;149:e96.
   PubMed Web of Science ®Google Scholar
• Souto Ferreira L, Canton O, da Silva RLP, et al. Assessing the best time interval between doses in a two-dose vaccination regimen to reduce the number of deaths in an ongoing epidemic of SARS-CoV-2. PLOS Comput Biol. 2022;18(3):e1009978.
   PubMed Web of Science ®Google Scholar
• Embi PJ, Levy ME, Naleway AL, et al. Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-nine states, January–September 2021. Am J Transplant. 2022;22(1):306–314.
   PubMed Web of Science ®Google Scholar
• Ward MP, Liu Y, Xiao S, et al. Challenges in the control of COVID-19 outbreaks caused by the Delta variant during periods of low humidity: an observational study in Sydney, Australia. Infect Dis Poverty. 2021;10(1):139.
   PubMed Web of Science ®Google Scholar